Latest filingSep 18, 2026Most recent Form 4
CBIO
CRESCENT BIOPHARMA, INC.
Insider activity for last month from 08/19 to 09/19. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$28.5M9 sells
Net open-market-$28.5M7 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period9transactions
- S · Open-market sells · dominant9 · 100%
Activity by reported role
A joint filing can contribute to multiple roles9transactions
- Chief executive officer · dominant2 · 22%
- PRES2 · 22%
- SR2 · 22%
- Chief financial officer1 · 11%
- CMO1 · 11%
- CSO1 · 11%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (7)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeMcNeill JonathanOrdinary Shares · Direct
134,588Sep 18, 2026
Brumm Joshua TOrdinary Shares · Direct
271,765Sep 18, 2026
Bispham Barbara HarlinOrdinary Shares · Direct
18,710Sep 16, 2026
Scalzo Richard WilliamOrdinary Shares · Direct
19,730Sep 16, 2026
Im Ellie EunkyungOrdinary Shares · Direct
21,446Sep 16, 2026
Pinkas JanOrdinary Shares · Direct
21,581Sep 16, 2026
Lynch RyanOrdinary Shares · Direct
13,631Sep 16, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 19 → Sep 19
LessMore
Top insiders
By absolute net value across the selected period- BT-$159.8k
- MJ-$77.2k
- PJ-$11.8k
- IE-$11.2k
- BH-$11.1k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
CBIO transaction history
Filters apply within this company and selected period by defaultLatest insider transactions
Form 4 filings from last month. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #225509 | CBIO | Lynch Ryan | SR | sale10b5-1 | 240 | -$429k | S | 09/18 | 09/16 |
| #225505 | CBIO | Pinkas Jan | CSO | sale10b5-1 | 658 | -$1.17M | S | 09/18 | 09/16 |
| #225504 | CBIO | Im Ellie Eunkyung | CMO | sale10b5-1 | 623 | -$1.11M | S | 09/18 | 09/16 |
| #225503 | CBIO | Scalzo Richard William | CFO | sale10b5-1 | 568 | -$1.01M | S | 09/18 | 09/16 |
| #225495 | CBIO | Bispham Barbara Harlin | SR | sale10b5-1 | 620 | -$1.10M | S | 09/18 | 09/16 |
| #225494 | CBIO | Brumm Joshua T | CEO | sale10b5-1 | 7.83k | -$13.0M | S | 09/18 | 09/18 |
| #225493 | CBIO | Brumm Joshua T | CEO | sale10b5-1 | 1.61k | -$2.88M | S | 09/18 | 09/16 |
| #225492 | CBIO | McNeill Jonathan | PRES | sale10b5-1 | 3.83k | -$6.41M | S | 09/18 | 09/18 |
| #225491 | CBIO | McNeill Jonathan | PRES | sale10b5-1 | 731 | -$1.30M | S | 09/18 | 09/16 |
CRESCENT BIOPHARMA, INC. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at CRESCENT BIOPHARMA, INC.?
Lynch Ryan, Pinkas Jan, Im Ellie Eunkyung, Scalzo Richard William, Bispham Barbara Harlin, Brumm Joshua T, McNeill Jonathan.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Brumm Joshua T reported a sale on Sep 18, 2026 valued at $13.0M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $285,500.96. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.